The receptors for GLP-1 are in the brain, so they should be there for some reason, but these drugs dont get in very well
However, when this process becomes overactive or uneven, it can lead to dark spots or an inconsistent complexion
insights from a range of social media platforms using a mixed-methods approach, Brain Sciences (2023) Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity, Food and Drug Administration (2024) Brain fog, Cleveland Clinic (2024) Associations of semaglutide with first-time diagnosis of Alzheimers disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US, Alzheimers & Dementia (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Availability of compounded GLP-1 medications may change based on FDA shortage determinations and enforcement priorities
So that is sort of where I see them functioning Best
Some early research is looking into its potential for fatty liver disease, sleep apnea, and even heart and kidney health
